Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approves |
gptkb:World_Health_Organization
|
| gptkbp:associatedWith |
vaccine hesitancy issues
WHO vaccination campaigns vaccine-derived disease |
| gptkbp:availableIn |
single-dose vial
|
| gptkbp:built |
infected mouse brain
|
| gptkbp:clinicalTrials |
conducted for safety and efficacy
|
| gptkbp:collaboratedWith |
research institutions
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
|
| gptkbp:contributedTo |
herd immunity
|
| gptkbp:developedBy |
gptkb:Max_Theiler
|
| gptkbp:distributes |
public health campaigns
|
| gptkbp:duration |
10 years
|
| gptkbp:evaluates |
high
|
| gptkbp:firstAwarded |
1937
|
| gptkbp:has |
1 dose
|
| gptkbp:historicalContext |
developed during yellow fever outbreaks.
|
| gptkbp:historicalSignificance |
first effective vaccine for yellow fever
|
| https://www.w3.org/2000/01/rdf-schema#label |
Theiler's vaccine
|
| gptkbp:impact |
required for entry into certain countries
significant reduction in yellow fever cases |
| gptkbp:influencedBy |
earlier yellow fever research
|
| gptkbp:influences |
public health policy
|
| gptkbp:innovation |
vaccine technology
|
| gptkbp:is_funded_by |
government and NGOs
|
| gptkbp:is_integrated_with |
routine immunization schedules
|
| gptkbp:is_monitored_by |
health authorities
|
| gptkbp:isRecognizedFor |
pregnant women
immunocompromised individuals |
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:linkedTo |
reduction in mortality rates
|
| gptkbp:locatedIn |
gptkb:South_Africa
|
| gptkbp:notable_player |
attenuated live virus vaccine
|
| gptkbp:notableEvent |
Nobel_Prize_in_Physiology_or_Medicine_for_Max_Theiler
|
| gptkbp:notableFigures |
gptkb:Max_Theiler
|
| gptkbp:partOf |
vaccination programs
global health initiatives |
| gptkbp:patentStatus |
patented
|
| gptkbp:producedBy |
various pharmaceutical companies
|
| gptkbp:promoted |
health organizations
|
| gptkbp:recognizedBy |
gptkb:CDC
|
| gptkbp:regulatoryCompliance |
licensed in many countries
|
| gptkbp:relatedTo |
yellow fever virus
|
| gptkbp:requires |
informed consent
|
| gptkbp:research |
long-term immunity effects
|
| gptkbp:researchInterest |
improved formulations
|
| gptkbp:sells |
YF-VAX
|
| gptkbp:sideEffect |
allergic reactions
mild fever local pain |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:subject |
international regulations
|
| gptkbp:suitableFor |
people over 9 months old
|
| gptkbp:supports |
every 10 years
|
| gptkbp:targets |
travelers to endemic areas
|
| gptkbp:type |
live attenuated vaccine
|
| gptkbp:usedFor |
prevention of yellow fever
|
| gptkbp:usedIn |
outbreak response
|